Tarperprumig Biosimilar – Anti-CFP and ALB mAb – Research Grade from ProteoGenix; catalogue PX-TA2088; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Tarperprumig Biosimilar – Anti-CFP and ALB mAb – Research Grade is a novel biotherapeutic agent that has been developed for the treatment of various diseases. This biosimilar is a combination of two monoclonal antibodies, Anti-CFP and ALB mAb, which target specific proteins involved in disease pathogenesis. In this article, we will provide a scientific description of the structure, activity, and applications of this biosimilar.
Tarperprumig Biosimilar is a complex molecule composed of two monoclonal antibodies, Anti-CFP and ALB mAb. These antibodies are produced by recombinant DNA technology and are identical to the naturally occurring antibodies in the human body. The structure of Tarperprumig Biosimilar is similar to that of the original drug, making it a highly effective and safe therapeutic option.
The two monoclonal antibodies in Tarperprumig Biosimilar have different mechanisms of action, which work together to provide a synergistic effect. Anti-CFP antibody specifically targets the CFP protein, which is known to play a crucial role in the pathogenesis of various diseases such as cancer, autoimmune disorders, and infectious diseases. By binding to CFP, the antibody inhibits its activity and prevents disease progression.
On the other hand, ALB mAb targets the ALB protein, which is involved in the regulation of immune responses. By binding to ALB, this antibody modulates the immune system and helps in the treatment of autoimmune disorders and inflammatory diseases. Additionally, ALB mAb also has anti-tumor activity, making Tarperprumig Biosimilar a potential therapeutic option for cancer treatment.
Tarperprumig Biosimilar has a wide range of applications in the treatment of various diseases. Its ability to target CFP and ALB proteins makes it a promising therapeutic option for the following conditions:
Cancer The anti-tumor activity of ALB mAb in Tarperprumig Biosimilar makes it a potential treatment for various types of cancers. By targeting ALB, this biosimilar can modulate the immune response against cancer cells and inhibit their growth and proliferation.
Autoimmune disorders are characterized by an overactive immune system that attacks healthy cells and tissues. Tarperprumig Biosimilar can be used to treat these conditions by targeting the ALB protein and modulating the immune response. This helps in reducing inflammation and preventing damage to the affected organs.
CFP protein is known to play a crucial role in the pathogenesis of infectious diseases. By targeting CFP, Anti-CFP antibody in Tarperprumig Biosimilar can inhibit the activity of this protein and prevent the spread of infection. This makes it a potential therapeutic option for various infectious diseases, including viral and bacterial infections.
Inflammatory diseases, such as rheumatoid arthritis and Crohn’s disease, are characterized by chronic inflammation. Tarperprumig Biosimilar can be used to treat these conditions by targeting the ALB protein and modulating the immune response. This helps in reducing inflammation and providing relief to patients.
Tarperprumig Biosimilar – Anti-CFP and ALB mAb – Research Grade is a novel biotherapeutic agent with a unique mechanism of action. Its combination of two monoclonal antibodies makes it a potent treatment option for various diseases, including cancer, autoimmune disorders, and infectious diseases. With its promising structure, activity, and applications, Tarperprumig Biosimilar has the potential to revolutionize the treatment of these conditions and improve patient outcomes.
ProteoGenix catalogue number PX-TA2088. For research use only.
Target: Tarperprumig Biosimilar – Anti-CFP and ALB mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Tarperprumig Biosimilar – Anti-CFP and ALB mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
